Drug
Safinamide clinical trials
Also written Xadago.
- studies test it
- 22
- open now
- 1
- in phase 3
- 9
- first study started
- 2004
Keep track of what changes. Save the safinamide studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
Development codes
Combined with it in one product
Studies by the year they started
22 studies that test it; most in 2019 (5)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2005 | 1 |
| 2007 | 3 |
| 2009 | 3 |
| 2010 | 2 |
| 2011 | 2 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 5 |
| 2021 | 1 |
| 2022 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 5
- Phase 3
- 9
- Phase 4
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 19 · Other 3
Newron Pharmaceuticals SPA (12) · Zambon SpA (5) · Eisai Korea Inc. (1) · IRCCS San Raffaele Roma (1) · Cross Research S.A. (1) · Universita di Verona (1) · Alain Kaelin (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses safinamide is read from its arms, and is right about nine times in ten.
Testing it · 22
- Safinamide vs Placebo for Pain in Patients With Parkinson's Disease and Motor FluctuationsRecruitingPhase 3Universita di VeronaNCT07761936Written as Safinamide
- Effect of Safinamide on Sleep Quality in Patients With Parkinson's DiseaseTerminatedPhase 4Alain KaelinNCT03968744Written as Safinamide
- A Study to Evaluate the Efficacy and Safety of Safinamide Mesilate as Add-on Therapy to Levodopa in Parkinson's Disease Participants With Motor Fluctuation in South KoreaCompletedPhase 4Eisai Korea Inc.NCT05312632Written as Safinamide Mesilate
- Overnight Switch From Rasagiline To SafinamideCompletedPhase 4IRCCS San Raffaele RomaNCT03843944Written as Safinamide
- A Study to Evaluate the Efficacy and Safety of Safinamide, as add-on Therapy, in Idiopathic Chinese Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Stable Doses of LevodopaCompletedPhase 3Zambon SpANCT03881371Written as Safinamide
- Effect of Safinamide on Parkinson's Disease Related Chronic PainCompletedPhase 4Zambon SpANCT03841604Written as Safinamide Methanesulfonate
- A Single and Multiple Dose Study to Assess How the Drug Enters, Moves Through and Exits the Body, Safety and Tolerability of Safinamide in Healthy Adult Chinese VolunteersCompletedPhase 1Zambon SpANCT03887221Written as Safinamide 50 mg
- Safinamide for Multiple System Atrophy (MSA)CompletedPhase 2Zambon SpANCT03753763Written as Safinamide Methanesulfonate
- Safinamide for Levodopa-induced Dyskinesia (PD-LID)WithdrawnPhase 3Zambon SpANCT03987750Written as Safinamide Methanesulfonate 150mg
- Open-Label Trial to Determine the Long-Term Safety of Safinamide in Parkinson's Disease PatientsTerminatedPhase 3Newron Pharmaceuticals SPANCT00865579Written as Safinamide
- A Study to Evaluate Safinamide's Effect on Dopamine and Serotonin's Availability by Using Brain ImagingTerminatedPhase 2Newron Pharmaceuticals SPANCT01264861Written as Safinamide
- Safinamide Steady State Interaction With RosuvastatinCompletedPhase 1Cross Research S.A.NCT03216304Written as 100 mg safinamide
- MOTION, Safinamide in Early IPD, as add-on to Dopamine AgonistCompletedPhase 3Newron Pharmaceuticals SPANCT00605683Written as Safinamide (as add-on therapy)
- Safinamide in Levodopa Induced Dyskinesia in Parkinson's Disease SubjectsCompletedPhase 2Newron Pharmaceuticals SPANCT01113320Written as Safinamide
- A Study to Assess the Effect of Hepatic Impairment on Safinamide PharmacokineticsCompletedPhase 1Newron Pharmaceuticals SPANCT01027169Written as safinamide
- Safinamide Renal Impairment TrialCompletedPhase 1Newron Pharmaceuticals SPANCT01374113Written as 50mg safinamide
- A Trial to Explore the Potential Benefit of Safinamide on Cognitive Impairment Associated With Parkinson's DiseaseCompletedPhase 2Newron Pharmaceuticals SPANCT01211587Written as safinamide
- A Study to Assess the Effect of Safinamide on Levodopa PharmacokineticsCompletedPhase 1/2Newron Pharmaceuticals SPANCT01026428Written as Safinamide + Levodopa
- 18-month Study of Long-term Efficacy & Safety of Safinamide as add-on Therapy in Patients With Mid-late Stage PDCompletedPhase 3Newron Pharmaceuticals SPANCT01286935Written as Safinamide
- Efficacy and Safety of Safinamide (50 and 100mg/Day) Versus Placebo, in Patients With Mid-late Stage Parkinson's DiseaseCompletedPhase 3Newron Pharmaceuticals SPANCT01187966Written as Safinamide
See all 22 studies that test safinamide →
As the comparator · 1 — what is tested is compared with safinamide
Codes
What other systems call safinamide · ClinicalTrials.gg INT003834
- MeSH (NLM) C092797safinamideConfirmed NLM, Wikidata
- UNII (FDA) 90ENL74SIGSAFINAMIDEConfirmed FDA, NLM, Wikidata
- RxNorm 1922448Confirmed FDA, Wikidata
- Wikidata Q2211523safinamideConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C76771SafinamideConfirmed FDA, Wikidata
- DrugBank DB06654One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C092797 | safinamide | Confirmed NLM, Wikidata |
| UNII (FDA) | 90ENL74SIG | SAFINAMIDE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1922448 | — | Confirmed FDA, Wikidata |
| Wikidata | Q2211523 | safinamide | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C76771 | Safinamide | Confirmed FDA, Wikidata |
| DrugBank | DB06654 | — | One source Wikidata |
Also registered as safinamide mesylate (UNII YS90V3DTX0 · RxNorm 1922449).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.